News
10 types of menopause innovation we want to see at the awards
One of the questions we hear most often from founders, clinicians, and product teams considering an entry to the Femtech World Awards is some version of: does what we do actually count?
The short answer is: probably yes. The longer answer is what this blog is for.
Menopause innovation is not a single category. It is a broad, fast-growing field that spans technology, clinical care, workplace culture, research and consumer health.
If your work touches the lives of people going through perimenopause, menopause, or post-menopause in any meaningful way, we want to hear from you.
Here are ten types of menopause innovation that are firmly within scope for this year’s awards.
1. Digital Health Platforms and Apps
From symptom trackers and personalised hormone cycle tools to AI-powered coaching apps and telehealth platforms, digital health is one of the most active spaces in menopause innovation right now.
If you have built a platform that helps people understand, manage, or navigate their menopause journey, this category is for you.
We are particularly interested in tools that go beyond generic content and offer genuinely personalised, evidence-informed support.
2. Diagnostics and Testing
Hormonal testing, at-home diagnostics, wearables that track physiological markers, and clinical tools that support earlier or more accurate diagnosis all fall within this space.
For too long, people have been dismissed or misdiagnosed because the tools simply were not sensitive or accessible enough.
Innovations that close this gap are exactly the kind of work this award was created to celebrate.
3. Therapeutics and Treatment Innovation
This includes both pharmaceutical and non-pharmaceutical approaches.
New formulations of hormone replacement therapy, novel delivery mechanisms, botanical or nutraceutical products with a strong evidence base, and non-hormonal treatments for specific symptoms such as vasomotor changes or genitourinary conditions are all eligible.
If you are developing or have developed something that genuinely works and can demonstrate that, we want to know about it.
4. Mental Health and Emotional Wellbeing
The psychological impact of menopause is still vastly under-discussed.
Anxiety, depression, cognitive changes, mood disruption, and loss of identity are experienced by a significant proportion of people going through this transition, yet the support available is often fragmented or absent altogether.
Products, programmes, and platforms that specifically address the mental health dimension of menopause are very much welcome here.
5. Workplace Solutions
Menopause is a workplace issue.
Symptoms can significantly affect concentration, confidence, and performance, and without the right support, many people reduce their hours, pass up promotions, or leave the workforce entirely.
Innovations in this space include employer-facing platforms, HR tools, training programmes, policy frameworks, and occupational health solutions that help organisations create genuinely supportive environments.
If you are working at the intersection of menopause and work, do not underestimate the value of what you are doing.
6. Sleep and Physical Symptom Management
Sleep disruption, hot flushes, joint pain, fatigue and weight changes are among the most commonly reported menopause symptoms, and the market for products addressing them directly is growing rapidly.
Whether you have developed a temperature-regulating wearable, a sleep support programme, a physiotherapy-informed exercise platform, or a product that addresses the physical experience of menopause in a new way, this is your category.
7. Sexual Health and Intimate Wellbeing
Genitourinary syndrome of menopause, changes to libido, vaginal dryness, and the broader impact of menopause on intimacy and relationships remain taboo subjects even within healthcare.
Innovators working to address these issues, whether through clinical products, consumer health solutions, education platforms, or therapeutic tools, are doing important work that deserves recognition.
We actively encourage entries in this space.
8. Research, Data, and Clinical Evidence
The evidence base for menopause care has historically been thin, and the people building it matter enormously.
Academic institutions, research organisations, and companies investing in clinical trials or real-world evidence generation are eligible for this award.
If your work is helping to shift what we know about menopause, how we understand its long-term effects, or how we evaluate interventions, that is innovation in the truest sense.
9. Education, Awareness, and Community
Changing the conversation around menopause is part of the innovation ecosystem.
Platforms, content brands, community spaces, and campaigns that are genuinely shifting awareness, reducing stigma, or building knowledge among patients, clinicians, or the wider public are eligible.
We are particularly interested in work that reaches underserved communities or addresses the significant disparities in menopause care across different demographics and ethnicities.
10. Integrated and Holistic Care Models
Some of the most exciting menopause innovation does not fit neatly into a single box.
Integrated care models that bring together clinical, lifestyle, and psychological support, multidisciplinary clinic models, whole-health platforms, and care pathways designed around the full experience of menopause rather than individual symptoms are exactly the kind of ambitious, systemic thinking this award is here to amplify.
Still Not Sure? Enter Anyway.
If you have read through this list and you are still asking yourself whether your work qualifies, the answer is almost certainly yes.
Our judges understand the full breadth of this field. They are not looking for perfection.
They are looking for genuine impact, clear thinking, and the ambition to do better for the millions of people whose menopause experience has, for too long, been an afterthought.
Find out more about the Femtech World Awards and enter for free here.
A new Female Health Hub launched by the English FA will support women and girls in grassroots football in England with trusted advice on health issues affecting play.
The hub brings together expert-backed guidance, practical tools and player insights in one place, giving women and girls practical advice and reassurance on female health in football.
It has four core aims: to help women and girls better understand their bodies and how female health affects performance and participation, to educate players on key health topics and when to seek further advice or support, to provide practical strategies to help navigate common female health challenges, and to help break down taboos and normalise conversations around female health in football.
Users of the hub will also be able to hear directly from members of the England women’s national team, who share their own experiences of navigating female health matters while playing at the highest level of the game.
“Our ambition is to create a game where women and girls can thrive,” said Sue Day, the FA’s director of women’s football.
“To achieve that, it’s essential that players feel supported in environments that understand and respond to their female health needs.
“We’ve heard directly from grassroots players that they want better information and support around female health, but that they often don’t know where to find it.
“The launch of the Female Health Hub marks an important step in changing the landscape.
“We want every player to feel confident in her own skin and supported without judgment, so she can feel empowered by her body, rather than held back by it.”
The platform was launched following research conducted by the FA that highlighted the need for better education and support around female health in football.
According to the FA, 88 per cent of adult players surveyed said their menstrual cycle has an impact on their ability to train or play, but 86 per cent reported they had never received education about the menstrual cycle in relation to football performance and training.
The research also found 64 per cent of women experience issues related to sports bras or breast health while playing football, despite sports bras being considered one of the most important pieces of playing kit.
Players also expressed strong interest in learning more about injury prevention, at 87 per cent, nutrition, at 84 per cent, and mental health, at 77 per cent, in relation to female health.
The first phase of the Female Health Hub focuses on three of the most requested topics: menstrual health, breast health and injury resilience, with further content to follow, including nutrition and pelvic health guidance.
The Royal College of Midwives (RCM) has referred to the women’s health strategy as a ‘missed opportunity’ to address maternity services.
The renewed strategy was released by the government this week, with the aim of putting women’s experiences at the centre of care and ensuring they are “better heard and served”.
However, the government stated that because of ongoing investigations into maternity services across the country, the strategy “does not seek to address safety in maternity and neonatal services”.
The RCM described this as a “missed opportunity” and urged the government to ensure that, following the inquiries, maternity is placed “at the very heart” of the strategy.
Gill Walton, RCM chief executive, said the college was “deeply disappointed” that maternity services “do not feature as a headline priority” in the renewed strategy.
She said: “This is a significant missed opportunity and one that is very difficult to understand.
“Pregnancy, birth and the postnatal period are not a footnote in women’s health – they are one of the most significant and consequential phases of a woman’s life.
“A strategy that treats maternity as an afterthought is not truly a women’s health strategy at all. It is exactly the kind of thinking that has allowed maternity services to reach the point they are at today.”
Walton acknowledged that the strategy contained commitments on ensuring women’s voices shape their care, on supporting families through pregnancy loss and on the principle that services should be held accountable when they fail to listen to women.
She added: “But a strategy that addresses one part of women’s health while leaving maternity care behind is only doing half the job.”
Walton urged the government to ensure that this is addressed when the ongoing investigations into maternity care conclude, with any recommendations placed “at the very heart of this strategy with the seriousness and urgency that women, families and midwives deserve”.
In the foreword to the renewed plans, health and social care secretary Wes Streeting referred to the ongoing independent National Maternity and Neonatal Investigation as action being taken by the government to improve safety in maternity services.
The strategy also refers to the new National Maternity and Neonatal Taskforce, chaired by Streeting, which aims to help deliver “safer, more equitable care” for women, babies and families.
The foreword said that, because of ongoing initiatives, it was “important that this work continues without restriction and that the government can properly respond to the findings”.
It added: “This renewed women’s health strategy therefore does not seek to address safety in maternity and neonatal services other than that related to women’s health before and during pregnancy and the actions we are taking immediately to improve maternity and neonatal care.”
The strategy does, however, include plans to prioritise health education in schools, communities and healthcare settings to “empower women” with the “knowledge and tools they need to help control their fertility” and “prepare for the best pregnancy outcomes.
It also promises to provide women with access to “safe and high-quality contraception, abortion care, fertility services, preconception care and support after pregnancy loss in convenient settings.
Article produced in association with London Pregnancy Clinic and Jeen Health
For the majority of couples planning a pregnancy, genetic testing is not something they think about until a problem arises.
Pre-conception genetic carrier screening challenges this approach by identifying risk before pregnancy begins.
As panel sizes have grown and at-home testing options have become widely available, carrier screening is transitioning from a niche clinical referral into a mainstream component of reproductive planning.
What Carrier Screening Tests For
Being a carrier of a genetic condition means carrying one copy of a variant in a gene associated with that condition, without being affected by it.
In most cases, carriers are entirely unaware of their status.
The clinical significance of carrier status emerges when both members of a couple carry a variant in the same gene: in this scenario, each pregnancy carries a one in four chance of resulting in a child who inherits two copies of the variant and is affected by the condition.
The conditions most frequently included in expanded carrier screening panels include cystic fibrosis, spinal muscular atrophy (SMA), fragile X syndrome, sickle cell disease, and a range of metabolic and enzyme deficiency disorders.
The Beacon 787 carrier test, offered by Jeen Health, screens for 787 conditions from a single sample, making it one of the most comprehensive panels currently available to UK families.
Who Is Most Likely to Benefit
Any couple planning a pregnancy can consider carrier screening. It is particularly relevant for:
- Couples with a family history of a known inherited condition
- Those from populations with higher carrier frequencies for specific conditions, including Ashkenazi Jewish, South Asian and African communities
- Couples pursuing fertility treatment, where genetic information informs treatment planning
- Those who wish to have the most complete picture of their reproductive health before conception
Importantly, being a carrier of a condition does not mean a child will be affected. It means there is a defined statistical risk that can be quantified, discussed and planned for with appropriate clinical support.
How the Test Is Performed
Carrier screening is typically carried out on a blood or saliva sample.
For at-home options such as the testing offered by Jeen Health, a cheek swab collection kit is dispatched to the patient, the sample is returned by post, and results are delivered digitally within a defined turnaround period.
In-clinic carrier testing may use a blood draw and provides the advantage of immediate access to a clinical consultation at the point of result delivery.
London Pregnancy Clinic offers genetics counselling through its partnership with Jeen Health, allowing couples to receive and contextualise carrier test results with expert support.
Genetic counselling before and after testing is recommended by Genomics England as a standard component of any genomic testing pathway.
What Happens If Both Partners Are Carriers
If both partners are identified as carriers for the same autosomal recessive condition, they are typically offered further counselling to discuss their options.
These may include proceeding naturally with an awareness of the risk, using prenatal diagnosis (CVS or amniocentesis) during pregnancy to test the fetus, or pursuing preimplantation genetic testing (PGT) in the context of IVF, which allows unaffected embryos to be selected before transfer.
The purpose of identifying carrier status before pregnancy is to give couples time to consider these options without the added pressure of an ongoing pregnancy.
Knowledge of carrier status does not remove reproductive choices; it expands the information available when making them.
The Role of Pre-Conception Services
Carrier screening sits within a broader category of pre-conception care that includes fertility assessments, general health optimisation and, where relevant, management of existing conditions before pregnancy begins.
London Pregnancy Clinic offers pre-conception services encompassing fertility investigations, genetics counselling and carrier testing as part of an integrated 0th trimester approach, allowing couples to address genetic and clinical risk factors before their pregnancy starts rather than after.
Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment.
Clinical guidance referenced reflects published NHS, NICE and RCOG standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article.
This piece was produced in association with London Pregnancy Clinic and Jeen Health, which provided background clinical information for editorial purposes.
Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
Entrepreneur3 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Menopause4 weeks agoCalifornia plans US$3.4m menopause care overhaul
Pregnancy3 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
Menopause4 weeks agoWatchdog bans five ads for women’s heath claims
Entrepreneur4 weeks agoWHIS USA 2026 announces first ticket release for landmark Women’s Health Innovation Summit
Menopause4 weeks agoMenopause has no lasting impact on cognition, research finds
News3 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion3 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
5 Comments